| Literature DB >> 31173852 |
Jianbing Huang1, Jiagen Li1, Yuan Li1, Zhiliang Lu1, Yun Che1, Shuangshuang Mao1, Yuanyuan Lei1, Ruochuan Zang1, Sufei Zheng1, Chengming Liu1, Xinfeng Wang1, Ning Li1, Nan Sun2, Jie He3.
Abstract
Interferons (IFNs) play crucial roles in the development and treatment of cancer. Long non-coding RNAs (lncRNAs) are emerging molecules involved in cancer progression. Here, we identified and characterized an IFN-inducible nuclear lncRNA IRF1-AS (Interferon Regulatory Factor 1 Antisense RNA) which was positively correlated with IRF1 expression. IFNs upregulate IRF1-AS via the JAK-STAT pathway. Knockdown and overexpression of IRF1-AS revealed that IRF1-AS inhibits oesophageal squamous cell carcinoma (ESCC) proliferation and promotes apoptosis in vitro and in vivo. Mechanistically, IRF1-AS activates IRF1 (Interferon Regulatory Factor 1) transcription through interacting with ILF3 (Interleukin Enhancer Binding Factor 3) and DHX9 (DExH-Box Helicase 9). In turn, IRF1 binds to the IRF1-AS promoter directly and activates IRF1-AS transcription. Global analysis of IRF1-AS-regulated genes indicated that IRF1-AS activates the IFN response in vitro and in vivo. IRF1 knockdown in IRF1-AS-overexpressing cells abolished the antiproliferative effect and activation of the IFN response. Furthermore, IRF1-AS was downregulated in ESCC tissues, and low expression correlated with poor prognosis. In conclusion, the interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma progression by promoting interferon response through a positive regulatory loop with IRF1.Entities:
Keywords: Esophageal squamous cell carcinoma; IRF1; IRF1-AS; Interferon; Long non-coding RNA
Mesh:
Substances:
Year: 2019 PMID: 31173852 DOI: 10.1016/j.canlet.2019.05.038
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679